Methods: Twenty-three patients with acute ischemic stroke were treated with 100 mg recombinant tissue plasminogen activator infused intravenously over 1 hour. Thrombolytic therapy was initiated 78 to 355 minutes after onset of symptoms.
Results: Angiography 16 to 24 hours after treatment in 17 patients showed patent intracranial arteries in 12, partial occlusion of the middle cerebral artery in 3, and total occlusion of the middle cerebral artery in 2. rCBF with '"Tc-hexamethylpropyleneamine oxime intravenously was measured 5 minutes before and within 24 hours after thrombolytic therapy in 12 patients. 10 of the 12 patients showed brain tissue reperfusion and 2, with angiographically documented middle cerebral artery occlusion, showed no reperfusion, thus documenting a relationship between reperfusion measured by regional cerebral blood flow and angiographic patency (P=.015). Three patients died. Patients who were reperfused within 24 hours (documented by repeated regional cerebral blood flow measurements) showed greater clinical improvement on the Scandinavian Stroke Scale the sooner their thrombolytic therapy was started and the more severe their neurological deficits.
Conclusions: Acute cerebral ischemia can be documented by rCBF measurements without delay of thrombolytic therapy, and repeated rCBF measurements can reveal whether cerebral reperfusion has occurred. In our study, early reperfusion was Included patients were treated with rt-PA (singlechain rt-PA, alteplase, Actilyse, Boehringer Ingelheim). A bolus of 15 mg was given intravenously over 2 minutes, followed by 85 mg IV during the subsequent hour. The dose of rt-PA was similar to that used in acute myocardial infarction (AMI). The infusion period was shortened to 60 minutes, with the aim of obtaining an intense but short-lasting systemic thrombolytic effect.
The patients were observed closely, with repeated clinical examinations and measurements of blood pressure over the next The clinical scoring on the SSS was performed by neurologists. The rCBF and angiographic data were compiled at the end of the study for independent blinded evaluation.
Results
Of the 77 patients screened, 54 were excluded for the following reasons. In 25 patients, the symptoms were very mild from the beginning, or partial or full remission of neurological deficits took place during the examination procedure. In 3 patients, delay from symptom onset exceeded 6 hours. One patient was excluded because of heart valve replacement surgery 10 days previously and 2 because of other increased risk of bleeding. Two patients were excluded owing to high blood pressure, 1 because informed consent was withheld, and 1 was a foreigner unable to give informed consent. Nineteen patients were excluded because of acute CT scan findings: 4 had hypodensities or edema in the relevant territory, 3 had old silent infarctions, and 12 had intracerebral hematomas.
Twenty-three patients were included in the study. Technical and logistical problems excluded 11 patients from repeated CBF measurements and 6 patients from angiography (Fig 1) . The main data from the patients are displayed in Table 1 17 .500 IU heparin 6 hours after thrombolytic therapy owing to a decreased level of consciousness and atrial fibrillation, developed a hematoma > 100 mL in the infarcted region and died on day 7 . Hemorrhagic transformation of the infarction occurred in 2 patients without clinical deterioration. The total dose of Actilyse was 100 mg except in 3 patients: 1 with body weight below 50 kg, 1 with a history of alcohol abuse, and 1 in whom the infusion was stopped because of gingival bleeding. In these 3 patients the dose ranged from 60 to 70 mg.
There was a statistically significant relationship between reperfusion measured by rCBF and the demonstration of complete or partially patent arteries by the cerebral angiography (P=.015, by Fisher's exact test). (Fig 2a) . In these patients, the more severe the initial neurological Although not proved, it is likely that the local ischemia observed in our patients was caused by vascular occlusion, and that the later increase of flow reflected lysis of thromboemboli (Fig 3) . The For abbreviation expansions and descriptions of infarcts, see Table 1 footnote.
The inverse correlation between late neurological improvement measured as score value on day 35 minus baseline and delay (Fig 2a) indicates that a large neurological improvement can be obtained if early reperfusion occurs. The significant inverse correlation between baseline score value and early clinical improvement measured as a 24-hour score value minus baseline (Fig 2b) suggests that a large early improvement can be obtained with a low baseline score, provided reperfusion is obtained. This phenomenon is even stronger when we correlate late neurological improvement (day 35 score value minus baseline) to baseline score value (Fig 2c) , which means that a large neurological late improvement will be obtained in a heavily damaged patient if reperfusion is obtained. The significance of these findings is that even patients with a severe clinical deficit will improve dramatically, provided early reperfusion is obtained. Early recanalization resulting in clinical recovery was also observed in a placebo-controlled double-blind trial24 in which early recanalization was achieved in 44% to 50% of the treated patients and the clinical recovery was significantly better in the recanalized group than in the nonrecanalized group.
In accordance with other studies,21,25 the results of the present study indicate that ICA occlusion is difficult to dissolve. In our study, 88% of the patients had partial or complete patency of the MCA at posttreatment angiography. This is in agreement with the findings of von Kummer et al.25 who reported that 86% of the patients were partially or completely recanalized after FIG Hemorrhagic transformation of the ischemic infarct occurred in 2 patients (9%). One of our patients died of a large intracerebral hematoma that could have been induced by a violation of our study protocol by the administration of 17.500 IU heparin after the thrombolytic therapy. Another patient suffered from bleeding from a gingival ulcer during the thrombolytic therapy, which caused termination of therapy after 60 mg. We observed no other bleeding complications, a finding that is in agreement with the results from previous pilot studies of thrombolytic therapy in acute ischemic stroke. 29 The Scandinavian Stroke Scale23 was used in this study because it is reliable in terms of low interobserver variation, can be performed rapidly, and provides an instrument for documentation of improvement or deterioration of neurological deficit.
Series comparing 9'9Tc-HMPAO images to SPECT images obtained by 133Xe as well as with C1502 positron emission tomographic images have consistently shown a good agreement in normal humans as well as in those with various diseases, including acute and chronic stroke.30,31 Furthermore, cerebral angiography performed at a time when SPECT showed hyperperfusion in a previously ischemic area never showed occlusion of the relevant artery. 32 We have recently found that 99mTc-HMPAO may overestimate the degree of reflow hyperemia in subacute stroke by up to 30%; 133Xe is used to indicate the true flow levels.33 This error of 99mTc-HMPAO does not, however, influence the conclusions about reperfusion in the acute phase after thromboiysis.
Our experience34 from a small pilot study of thrombolytic therapy in acute stroke was that a small and insufficient intra-arterial dose of UK or porcine plasmin, which failed to evoke a systemic thrombolytic effect, could not reperfuse the occluded arteries. The present results suggest that reperfusion of large ischemic areas does not lead to dangerous edema formation. On the contrary, the patients who showed early reperfusion improved rapidly and developed small infarcts.
The goal of thrombolytic therapy is to administer an adequate dose within the shortest time delay at which the reperfusion efficacy and the safety in terms of low serious bleeding complications is optimal.
